Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
Marion Escudier, Jennifer Cautela, Nausicaa Malissen et al. · Circulation · 2017
International audience
Cited by 517 works. doi:10.1161/circulationaha.117.030571 Open-access PDF
Authors
- Marion Escudier
- Jennifer Cautela
- Nausicaa Malissen
- Yann Ancédy
- Morgane Orabona
- Johan Pinto
- Sandrine Monestier
- Jean‐Jacques Grob
- Ugo Scemama
- Alexis Jacquier
- Nathalie Lalevée
- Jérémie Barraud
- Michaël Peyrol
- Marc Laine
- Laurent Bonello
- Franck F. Paganelli
- Ariel A. Cohen
- Fabrice Barlési
- Stéphane Éderhy
- Franck Thuny
References
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- Cardiovascular Toxicities Associated with Cancer Immunotherapies
- New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
- Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung